NRF2 regulates serine biosynthesis in non-small cell lung cancer

Nature Genetics

Volumn 47, Issue 12, 2015, Pages 1475-1481

  DeNicola, Gina M ^a   Chen, Pei Hsuan ^b   Mullarky, Edouard ^a   Sudderth, Jessica A ^b   Hu, Zeping ^b   Wu, David ^a   Tang, Hao ^b   Xie, Yang ^b   Asara, John M ^c   Huffman, Kenneth E ^d   Wistuba, Ignacio I ^e   Minna, John D ^d   DeBerardinis, Ralph J ^b   Cantley, Lewis C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; GLUTATHIONE; GLYCINE; NUCLEOTIDE; SERINE; TRANSCRIPTION FACTOR NRF2; MESSENGER RNA; NFE2L2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR MARKER;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CANCER PROGNOSIS; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MALE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHGDH GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSAT1 GENE; SHMT2 GENE; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG SCREENING; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; NF-E2-RELATED FACTOR 2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SERINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949102276     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3421     Document Type: Article

References (31)

1. Vander Heiden, M.G., Cantley, L.C. & Thompson, C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
2. Locasale, J.W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869-874 (2011).
3. Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350 (2011).
4. Mullarky, E., Mattaini, K.R., Vander Heiden, M.G., Cantley, L.C. & Locasale, J.W. PHGDH amplification and altered glucose metabolism in human melanoma. Pigment Cell Melanoma Res. 24, 1112-1115 (2011).
5. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
6. Mootha, V.K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
7. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
8. Ye, J. et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad. Sci. USA 109, 6904-6909 (2012).
9. Miyamoto, N. et al. Transcriptional regulation of activating transcription factor 4 under oxidative stress in retinal pigment epithelial ARPE-19/HPV-16 cells. Invest. Ophthalmol. Vis. Sci. 52, 1226-1234 (2011).
10. Afonyushkin, T. et al. Oxidized phospholipids regulate expression of ATF4 and VEGF in endothelial cells via NRF2-dependent mechanism: novel point of convergence between electrophilic and unfolded protein stress pathways. Arterioscler. Thromb. Vasc. Biol. 30, 1007-1013 (2010).
11. Ye, P. et al. Nrf2-and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol. Cell. Biol. 34, 3421-3434 (2014).
12. He, C.H. et al. Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. J. Biol. Chem. 276, 20858-20865 (2001).
13. Harding, H.P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099-1108 (2000).
14. Hayes, J.D. & McMahon, M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34, 176-188 (2009).
15. Kim, Y.R. et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 220, 446-451 (2010).
16. Konstantinopoulos, P.A. et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 71, 5081-5089 (2011).
17. Seng, S. et al. NRP/B mutations impair Nrf2-dependent NQO1 induction in human primary brain tumors. Oncogene 28, 378-389 (2009).
18. Zhang, P. et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 9, 336-346 (2010).
19. Shibata, T. et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA 105, 13568-13573 (2008).
20. Solis, L.M. et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin. Cancer Res. 16, 3743-3753 (2010).
21. Singh, A. et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68, 7975-7984 (2008).
22. DeNicola, G.M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109 (2011).
23. Ohta, T. et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68, 1303-1309 (2008).
24. Mitsuishi, Y. et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66-79 (2012).
25. Singh, A. et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J. Clin. Invest. 123, 2921-2934 (2013).
26. Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl. Acad. Sci. USA 108, 8674-8679 (2011).
27. Mullen, A.R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388 (2012).
28. Yuan, M., Breitkopf, S.B., Yang, X. & Asara, J.M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872-881 (2012).
29. Shedden, K. et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 14, 822-827 (2008).
30. Rädle, B. et al. Metabolic labeling of newly transcribed RNA for high resolution gene expression profiling of RNA synthesis, processing and decay in cell culture. J. Vis. Exp. doi:10.3791/50195 (8 August 2013).
31. Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107 (2009).